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Marietta Iacucci, MD, PhD1,3Cancer immunotherapy with the use of checkpoint in-
hibitors, ipilimumab (anti-cytotoxic T lymphocyte antigen)
or nivolumab, pembrolizumab, and atezolizumab (anti-pro-
grammed death-1) may induce colitis, an increasinglyormal appearance of the cecum under high-deﬁnition white-
opy.
igh-deﬁnition white-light colonoscopic view showing granular
ciﬁc appearances of the ileal mucosa.
GIE.orgrecognized immune-mediated adverse event (IrAE). The
spectrum of endoscopic ﬁndings at colonoscopy has not
been deﬁned comprehensively; Crohn’s-like and ulcerative
colitis–like changes have been described.1,2 Colitis is mostFigure 3. Narrow-band image easily showing microerosions and hyper-
trophy of the villi.
Figure 4. Biopsy specimens from the ileum showing congested and
edematous villi with otherwise preserved architecture (H&E, orig.
mag. 100).
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Figure 5. Biopsy specimens from the ileum showing edematous villi with
extravasated red blood cells (*) and scattered eosinophils (/) (H&E,
orig. mag. 200).
Figure 6. Biopsy specimens from the cecum showing a mild increase in
eosinophils (/) (H&E, orig. mag. 200).
Video Case Report Smith et alcommonly described, although ileoscopy is not always con-
ducted. IrAEs are more common with ipilimumab than
with anti-PD1 monoclonal antibodies, although increas-
ingly, patients are being exposed to a combination or
sequential use of both classes of immunotherapy.
We report a patient presenting with diarrhea after treat-
ment with ipilimumab and nivolumab with subtle ileal
changes visible only by electronic virtual chromoendo-
scopy after white-light endoscopy did not detect abnormal-
ities (Video 1, available online at www.VideoGIE.org).
A 44-year-old woman with metastatic melanoma, treated
with intravenous nivolumab 1 mg/kg and intravenous ipili-
mumab 3 mg/kg weekly, developed diarrhea. Flexible
sigmoidoscopy showed macroscopically normal tissues,
but biopsy specimens demonstrated apoptotic nuclear
debris in the superﬁcial lamina propria. She was treated
for immune-related colitis with oral prednisolone (1 mg/
kg), but when she was weaned from the prednisolone,
her diarrhea worsened, with watery stools (up to 7 per
day) requiring hospital admission. A repeated colonoscopy
showed a normal colon with no perceptible changes under
high-deﬁnition white-light endoscopy and narrow-band im-
aging (Olympus Evis Lucera Elite CB290 series; Tokyo,
Japan) (Fig. 1). Further examination of the terminal
ileum with narrow-band imaging (with and without near
focus) revealed mild to moderate ileitis with microerosions
and hypertrophy of villi for at least 30 cm (Figs. 2 and 3).
Biopsy specimens from the ileum and colon showed
mild edema, congestion of villi with patchy borderline in-
crease in eosinophils within the lamina propria, and prom-
inent Peyer’s patches in the terminal ileum (Figs. 4 and 5).
A mild increase in eosinophils in cecal biopsies may
represent checkpoint inhibitor microscopic colitis (Fig. 6).
These abnormalities were distinct and different from a
Crohn’s disease-like appearance of the distal ileum.
Nivolumab is an anti-PD1 antibody and is a checkpoint
inhibitor. A case series of 20 patients with immune-mediated134 VIDEOGIE Volume 4, No. 3 : 2019gastroenterocolitis associated with PD-1 inhibitors summa-
rizes the endoscopic ﬁndings that can be encountered.3
Endoscopic features may include normal mucosa, mild
erythema, focal erosions, congested/granular mucosa, and
ulceration. These features can be patchy, with apparent
distal sparing of the disease. Two patients from the case
series had ileitis without colonic involvement.3 It has been
suggested that checkpoint-inhibitor colitis may represent a
distinct type of inﬂammatory bowel disease; Bertha et al4
described a case of ipilimumab-induced colitis transforming
into a Crohn’s colitis-like phenotype with severe deep ulcera-
tion and skip lesions. Although theendoscopic and clinical fea-
tures may be similar to those of inﬂammatory bowel disease,
there are key differences histologically, with an acute inﬂam-
matory histologic proﬁle associated more with checkpoint-in-
hibitor–associated colitis.3 As in our case, although the ileum
was involved, the histologic appearance was not consistent
with Crohn’s disease. The endoscopic appearance of the
ileum did not have aphthous ulcers, linear ulcers,
cobblestoning, or vascular pattern changes.
Diarrhea and colitis can be delayed after checkpoint inhib-
itor treatment; therefore, a low index of suspicion should
be maintained.2 Endoscopic assessment can help predict
response to treatment because the presence of ulcerations
predicts a poor response to steroids.5 Although limited
examinations with rectosigmoidoscopy may allow endo-
scopic assessment and biopsies with less-intensive bowel
preparation, clinicians need to be mindful of not missing
cases of ileitis without colonic involvement. This case
illustrates the importance of using advanced endoscopic
imaging with electronic chromoendoscopy and thorough
colonoscopic examination of patients with suspected GI
side effects as an IrAE, including ileal intubation to
enhance mucosal abnormalities allowing targeted bi-
opsies. We have shown that the endoscopic changes
may be subtle and appear different from those of Crohn’s
disease.www.VideoGIE.org
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